TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37886040
Drug: Residential substance
Normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residential substance use treatment
Study: 37886114
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for 12 weeks
Study: 37886114
Drug: Play-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Play-based therapy for 12 weeks
Study: 37886458
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10mg PO plus standard treatment
Study: 37886645
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor (SSTR)-2+ treatment
Study: 37886872
Drug: P2B001 (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2B001 (0.6 mg pramipexole and 0.75 mg rasagiline)
Study: 37887975
Drug: Leucine supplementation
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine supplementation (6 g/day)
Study: 37888914
Drug: Inhaled amikacin
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amikacin (20 mg/kg ideal body weight once daily for 3 days)
Study: 37888914
Drug: Inhaled amikacin
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amikacin
Study: 37888917
Drug: Nemolizumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab (60 mg initial dose, followed by 30 mg or 60 mg every 4 weeks for 16 weeks)
Study: 37888916
Drug: Patisiran (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran (0.3 mg/kg body weight, once every 3 weeks for 12 months)
Study: 37889100
Drug: PICU Supports
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICU Supports intervention involving trained family navigators who assessed and addressed parent needs, offered weekly family meetings, and provided post-PICU discharge check-ins.
Study: 37889107
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma with a neutralizing antibody titer of at least 1:320 (or 1:160 for 17.7% of patients)
Study: 37889308
Drug: 24-week exercise
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24-week exercise intervention during BEP-chemotherapy (group A)
Study: 37889308
Drug: 24-week exercise
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24-week exercise intervention after BEP-chemotherapy (group B)
Study: 37889382
Drug: Pemigatinib 13.5
Normalized name: pemigatinib 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemigatinib 13.5 mg once daily (QD) on a 2-weeks-on/1-week-off schedule
Study: 37889486
Drug: 1.62% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% testosterone gel daily
Study: 37889486
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel daily
Study: 37889513
Drug: RTS,S/AS02A malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS02A malaria vaccine
Study: 37889522
Drug: BI 685509
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 685509 (2 mg BID)
Study: 37889522
Drug: BI 685509
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 685509 (3 mg BID)
Study: 37889522
Drug: BI 685509
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 685509 (1, 2, or 3 mg BID)
Study: 37889541
Drug: Varenicline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline + Oral NRT (VAR+NRT)
Study: 37889541
Drug: Smartphone medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone medication reminders (REM)
Study: 37889541
Drug: Varenicline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline + Oral NRT (VAR+NRT) with reminders (REM)
Study: 37889541
Drug: Overall medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall medication adherence (assessed via the Medication Adherence Questionnaire)
Study: 37890035
Drug: Low-density lipoprotein
Normalized name: Low-density lipoprotein receptor kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-density lipoprotein (LDL) levels < 100 mg/dL
Study: 37890351
Drug: Nivolumab (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (360 mg) plus eribulin (1.4 mg/m²)
Study: 38805733
Drug: Low-level light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level light therapy (LLLT)
Study: 37890960
Drug: Xylitol syrup
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol syrup (two times per day for 6 months)
Study: 37890960
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup with sorbitol (two times per day for 6 months)
Study: 37890960
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup with sorbitol
Study: 37890987
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) with medical care in No-IVT stratum
Study: 37890987
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) with medical care in IVT stratum
Study: 37890987
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) in IVT stratum
Study: 37890987
Drug: No-Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-Endovascular therapy (No-EVT) in IVT stratum
Study: 37890987
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) in No-IVT stratum
Study: 37890987
Drug: No-Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-Endovascular therapy (No-EVT) in No-IVT stratum
Study: 37891072
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of treatment (Cohort A, n=10)
Study: 37891072
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of treatment (Cohort B, n=10)
Study: 37891072
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events (AEs) related to treatment
Study: 37891178
Drug: EPP-AF® (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPP-AF® (900 mg/day for 10 days)
Study: 37891226
Drug: Zinc and
Normalized name: Zinc and/or zinc compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc and vitamin E supplementation (1200 IU vitamin E and 120 mg elemental zinc the day before surgery, followed by 30 mg zinc and 200 IU vitamin E daily from the 2nd day after surgery to 3 weeks)
Study: 37891522
Drug: Fluoxetine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine combined with cognitive-behavioural therapy (CBT)
Study: 37891522
Drug: Sertraline, vortioxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, vortioxetine, or duloxetine (for nonresponders)
Study: 37891522
Drug: Aripiprazole, olanzapine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole, olanzapine, or lithium carbonate added to fluoxetine (for nonresponders)
Study: 37891549
Drug: 2% HA
Normalized name: GNP Antibacterial 2% Hand Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% HA gel with PBMT (diode laser 980 nm, 0.2 W)
Study: 37891566
Drug: Concerns about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerns about medication
Study: 37891566
Drug: Beliefs about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beliefs about overprescribing medication
Study: 37891574
Drug: Perioperative mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative mental health (PMH) bundle including behavioral activation (BA) and medication optimization (MO)
Study: 37891608
Drug: PACAP (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACAP (0.1 mg/ml, 6 μl, intranasally for 4 weeks)
Study: 37891616
Drug: Oral fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fosfomycin
Study: 37891681
Drug: PEERNaija app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PEERNaija app (Arm 1) - includes daily medication reminders, peer-based social incentives, and virtual peer social support.
Study: 37892573
Drug: Norepinephrine Zero-Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine Zero-Bolus High-Infusion (Group ZBHI, 0 µg/0.1 µg kg)
Study: 37892573
Drug: Norepinephrine (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (other dosing schemes not specified)
Study: 37892656
Drug: Normal life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal life with emphasis on glycemic controls before and after daily physical exercise.
Study: 37893050
Drug: Daily change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily change of PSP
Study: 37893050
Drug: Daily change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily change of CRP
Study: 37893050
Drug: Daily change
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily change of PCT
Study: 37894368
Drug: Pre-operative mechanical
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative mechanical bowel preparation
Study: 37894732
Drug: Sirolimus (0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (0.5-2 mg/day)
Study: 37896832
Drug: Higher HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher HIV-1 Env gp120-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity
Study: 37897395
Drug: Stromal vascular
Normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stromal vascular fraction injection
Study: 37897472
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of allogeneic off-the-shelf CD45RA T cells
Study: 37897566
Drug: Prebiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic treatment
Study: 37897566
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro effect of metformin
Study: 37897866
Drug: Matched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched therapy recommended by multidisciplinary tumor board (MTB)
Study: 37897866
Drug: Treatment based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment based on genomic profiling
Study: 37898146
Drug: Oral PrEP
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PrEP (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate)
Study: 37898148
Drug: At least
Normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least two doses of wild-type mRNA vaccine alone
Study: 37898184
Drug: Ozanimod (OZA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod (OZA), oral, once daily, incremental dosage for a maximum of 14 days
Study: 37898410
Drug: CS-2034 low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CS-2034 low-dose (30 μg of mRNA)
Study: 37898410
Drug: CS-2034 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-2034 high-dose (50 μg of mRNA)
Study: 37898410
Drug: Placebo (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.3 ml type 5 adenovirus vector for low-dose; 0.5 ml type 5 adenovirus vector for high-dose)
Study: 37898741
Drug: At-home, self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home, self-administered COVID-19 testing kits distributed to participants.
Study: 37898759
Drug: Cerebral oximetry
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral oximetry monitoring during mechanical ventilation according to SafeBoosC treatment guideline.
Study: 37898781
Drug: mHealth-based self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth-based self-management intervention (AEGORA) via Sidekick app with weekly prompts
Study: 37898781
Drug: mHealth-based self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth-based self-management intervention (AEGORA) via Sidekick app with monthly prompts
Study: 37899297
Drug: Sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib plus triplet therapy with venetoclax, azacitidine, and homoharringtonine (VAH)
Study: 37899433
Drug: High-dose pharmaceutical-grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pharmaceutical-grade biotin (100 mg taken orally three times a day over a maximum of 52 weeks)
Study: 37899433
Drug: High-dose pharmaceutical-grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pharmaceutical-grade biotin
Study: 37899826
Drug: ASP (iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP (iron supplement)
Study: 37899826
Drug: FS administered
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS administered as a single weekly dose of 420 mg Fe
Study: 37899826
Drug: FS administered
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS administered daily at 60 mg Fe/day
Study: 37899826
Drug: FS plus
Normalized name: MILK THISTLE 6 [hp_X] in 1 mL / HELIANTHEMUM CANADENSE 6 [hp_X] in 1 mL / SOLANUM DULCAMARA TOP 6 [hp_X] in 1 mL / GALIUM APARINE 6 [hp_X] in 1 mL / MAGNESIUM CHLORIDE 6 [hp_X] in 1 mL / SODIUM SULFATE 6 [hp_X] in 1 mL / VISCUM ALBUM FRUITING TOP 6 [hp_X] in 1 mL / HYDROCHLORIC ACID 6 [hp_X] in 1 mL / ESTRONE 8 [hp_X] in 1 mL / SODIUM CHLORIDE 10 [hp_X] in 1 mL / AILANTHUS ALTISSIMA FLOWERING TWIG 12 [hp_X] in 1 mL / BARIUM CHLORIDE DIHYDRATE 12 [hp_X] in 1 mL / CADMIUM 12 [hp_X] in 1 mL / CEANOTHUS AMERICANUS LEAF 12 [hp_X] in 1 mL / ANAMIRTA COCCULUS SEED 12 [hp_X] in 1 mL / IRIDIUM 12 [hp_X] in 1 mL / THUJA OCCIDENTALIS LEAFY TWIG 12 [hp_X] in 1 mL / CINCHONA OFFICINALIS BARK 12 [hp_X] in 1 mL / OYSTER SHELL CALCIUM CARBONATE, CRUDE 12 [hp_X] in 1 mL / CROTALUS DURISSUS TERRIFICUS VENOM 16 [hp_X] in 1 mL ORAL LIQUID [EBV/CFS Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS plus a micronutrient powder (MNP) administered daily at 60 mg Fe/day
Study: 37900876
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment + Dry Needling (DN)
Study: 37901358
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention using Nordic walking poles, personalized physician exercise prescriptions, pedometers, and access to exercise videos.
Study: 37902726
Drug: BIIB080 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB080 (10 mg every 4 weeks, 30 mg every 4 weeks, 60 mg every 4 weeks, 115 mg every 12 weeks)
Study: 37902726
Drug: BIIB080 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB080 (60 mg every 12 weeks, 115 mg every 12 weeks) during long-term extension
Study: 37902732
Drug: Steady concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady concentration PD with 11 g/h glucose dose
Study: 37902732
Drug: Steady concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady concentration PD with 14 g/h glucose dose
Study: 37902732
Drug: Steady concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady concentration PD with 20 g/h glucose dose
Study: 37902732
Drug: Standard 4-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 4-hour CAPD dwell with 2 L of 2.5% dextrose solution (control)
Study: 37902814
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (standard support from their employer)
Study: 37902861
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor signaling inhibitors (ARSi)
Study: 37902990
Drug: Novel anti-NRP2
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Novel anti-NRP2 antibody
Study: 37903153
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of oral hygiene
Study: 37903324
Drug: Aspacytarabine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspacytarabine 4.5 g/m2 per day for 6 doses
Study: 37903324
Drug: Aspacytarabine in
Normalized name: Aspacytarabine
DrugBank: Aspacytarabine (DB17226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspacytarabine in patients with prior treatment with hypomethylating agents
Study: 37903325
Drug: Durvalumab before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab before JCAR014 infusion
Study: 37903325
Drug: Ongoing durvalumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing durvalumab therapy after JCAR014
Study: 37903440
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered (2,296 antibiotic regimens; 95.7% intravenous, 4.3% oral)
Study: 37903440
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed and administered on admission day
Study: 37903440
Drug: Dosing accuracy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing accuracy of intravenous ciprofloxacin regimens
Study: 37903440
Drug: Intravenous-to-oral switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous-to-oral switch
Study: 37903440
Drug: Adult-dose tablets
Normalized name: hepatitis A vaccine (inactivated) strain HM175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult-dose tablets splitting
Study: 37903465
Drug: Exogenous LH
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous LH administration during ovarian stimulation
Study: 37903483
Drug: BI 690517
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 690517 (3 mg, 10 mg, or 20 mg)
Study: 37903504
Drug: Neoadjuvant nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant nivolumab plus chemotherapy
Study: 37903590
Drug: Atezolizumab (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (adjuvant treatment)
Study: 37904082
Drug: 0.1% loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% loading dose for six months followed by 0.01% for six months (N=33)
Study: 37904241
Drug: Haloperidol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2.5 mg IV every 8 hours, titrated up to 5 mg if delirium persisted until ICU discharge or up to 14 days
Study: 37904247
Drug: TH-SC01 cells
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-SC01 cells (120 million cells, single intralesional injection)
Study: 37904250
Drug: Sirolimus (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (2 mg/day for 5-7 days)
Study: 37904314
Drug: Seladelpar 5
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 5 or 10 mg orally once daily
Study: 37904861
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication intake
Study: 37905356
Drug: Tablet fasted
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet fasted (100 mg peposertib)
Study: 37905356
Drug: Tablet fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet fed (100 mg peposertib)
Study: 37905356
Drug: OS fasted
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS fasted (100 mg peposertib)
Study: 37905421
Drug: 2-week patch
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week patch monitors for AF screening
Study: 37906649
Drug: SOC Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC Chemotherapy + Trastuzumab (Arm C)
Study: 37906726
Drug: Ofranergene obadenovec
Normalized name: Ofranergene obadenovec
DrugBank: Ofranergene obadenovec (DB15175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofranergene obadenovec (ofra-vec) with weekly paclitaxel
Study: 37906726
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with weekly paclitaxel
Study: 37907210
Drug: pyrotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrotinib (400 mg once daily) combined with trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2)
Study: 37907210
Drug: placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo combined with trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2)
Study: 37907210
Drug: pyrotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrotinib (400 mg once daily)
Study: 37907221
Drug: NIZ985 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIZ985 (1 µg/kg TIW)
Study: 37907221
Drug: NIZ985 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIZ985 (1 µg/kg TIW) + spartalizumab (400 mg Q4W)
Study: 37907221
Drug: NIZ985 (single-agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIZ985 (single-agent)
Study: 37907482
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (i.v. thrombolysis)
Study: 37907503
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Immunity-and-matrix-regulatory cells (IMRCs)
Study: 37907503
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of umbilical cord MSCs (as a comparison)
Study: 37907796
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg L-citrulline every 6 hours for 72 hours
Study: 37907858
Drug: Multilevel mobility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel mobility intervention (information and exercise booklets, mobility diary, iPad with exercise videos, e-learning for healthcare professionals, oral presentation, mobility checklist, posters and pictures on the wards)
Study: 37910157
Drug: Goal2Quit mobile
Normalized name: CHAMAEMELUM NOBILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal2Quit mobile app intervention with a 2-week sample of combination nicotine replacement therapy (NRT)